Alkermes ALKS
NASDAQ ALKS
$45.38 -0.11 (-0.24%)
As of: Sep 9, 2026 · 3:28 PM EDT

Alkermes (ALKS) Depreciation & Amortization (CF) (2011 - 2026)

Alkermes' (ALKS) quarterly Depreciation & Amortization (CF) came in at $30.3 million in Q2 2026, up 287.26% year-over-year from $7.8 million in Q2 2025, and up 55.83% quarter-over-quarter from $19.4 million in Q1 2026.

Analysis

Alkermes (ALKS) Depreciation & Amortization (CF) (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $30.3 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 287.26% year-over-year to $30.3 million in Q2 2026; TTM through Jun 2026 was $61.6 million, a 112.1% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, down 4.79% from the prior year.
  • Depreciation & Amortization (CF) was $30.3 million for Q2 2026 at Alkermes, up from $19.4 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $30.3 million in Q2 2026 and troughed at $3.8 million in Q4 2025.
  • A 5-year average of $14.3 million and a median of $18.6 million in 2023 frame the typical range for Depreciation & Amortization (CF).
  • Across the five-year window, Depreciation & Amortization (CF) tumbled 64.98% in 2024 and surged 287.26% in 2026, its largest moves.
  • Over 5 years, Depreciation & Amortization (CF) stood at $19.7 million in 2022, then decreased by 5.77% to $18.5 million in 2023, then slumped by 63.07% to $6.8 million in 2024, then tumbled by 43.83% to $3.8 million in 2025, then jumped by 687.21% to $30.3 million in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $30.3 million (Q2 2026), $19.4 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Johnson & Johnson 645.93 Bn 625.17 Bn 17.26 Bn 1.96 Bn
2 AbbVie 443.06 Bn 436.49 Bn 12.70 Bn -
3 Merck 365.76 Bn 358.62 Bn 12.21 Bn -
4 Novartis Ag 266.47 Bn 258.78 Bn 11.24 Bn -
5 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn 1.62 Bn
6 Sanofi 52.36 Bn 44.98 Bn 10.79 Bn 3.97 Bn
7 Revolution Medicines 43.97 Bn 43.97 Bn - -
8 Incyte 25.42 Bn 20.88 Bn 1.57 Bn 26.48 Mn
9 United Therapeutics 21.52 Bn 18.86 Bn 683.80 Mn 24.20 Mn
10 Alkermes 7.58 Bn 6.93 Bn 397.90 Mn 30.28 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 30.28 Mn
Mar 31, 2026 19.43 Mn
Dec 31, 2025 3.85 Mn
Sep 30, 2025 8.08 Mn
Jun 30, 2025 7.82 Mn
Mar 31, 2025 7.42 Mn
Dec 31, 2024 6.85 Mn
Sep 30, 2024 6.97 Mn
Jun 30, 2024 6.66 Mn
Mar 31, 2024 8.06 Mn
Dec 31, 2023 18.54 Mn
Sep 30, 2023 18.66 Mn
Jun 30, 2023 19.01 Mn
Mar 31, 2023 18.71 Mn
Dec 31, 2022 19.68 Mn
Sep 30, 2022 19.60 Mn
Jun 30, 2022 19.39 Mn
Mar 31, 2022 19.20 Mn
Dec 31, 2021 21.14 Mn
Sep 30, 2021 19.39 Mn